|
A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies Clinical research trials and A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies. A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies clinical trial. Subjects frequently obtain the most expert healthcare possible for their A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies  A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies
A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies
For Condition: Esophageal Neoplasms,Colorectal Neoplasms,Neoplasms,Ovarian Neoplasms,Pancreatic Neoplasms,Hepatocellular Carcinoma
Status: No longer recruiting
Sponsor(s): Aronex Pharmaceuticals ,
Synopsis: To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
Details: Primary Objective: - Determine response rate (RR; complete and partial response [CR, PR]) and duration after therapy with Aroplatin™ in patients with advanced solid malignancies. Secondary Odjective: - Determine the safety and tolerability of Aroplatin
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Advanced solid malignancies; - Amenable to therapy with DACH platinum agents; - Measurable disease (RECIST criteria); - ECOG performance score of 0-2; - Adequate hematopoietic, liver and renal function; - Adequate cardiac function (maximum of class II, NYHA); - Women of childbearing potential must have a negative urine or serum pregnancy test; - Signed written informed consent; - Subjects must be willing to be followed during the course of treatment/observation and follow-up. Exclusion Criteria: - No other active malignancies; - No prior therapy with oxaliplatin; - No known brain metastases; - Active, uncontrolled infection or other serious medical illnesses; - Not using or have used any investigational therapy during four weeks before start of protocol treatment.
Total Enrollment: 40
Location and Contact Information:
John Wayne Cancer Institute
Santa Monica, California, 90404
United States
Additional Information:
Study ID Numbers: C-726-04;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057395
Other Ovarian Neoplasms Studies:
1. Kanglaite Injection Phase I Study
2. Cord Blood Stem Cell Transplantation Study (COBLT)
3. Phase I Study of HeFi-1 to Treat Cancers with CD30 Protein
4. Collection of Blood, Bone Marrow, Tumor or Tissue Samples
5. Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
Related Studies:
Other Ovarian Neoplasms Clinical Trials
Other California Clinical Trials
Other Santa Monica Clinical Trials
A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Solid Malignancies
|
|
|
|
|
|
|
|
